The French drugmaker announced early Friday that the Food and Drug Administration has approved its Lovenox blood thinner for treatment of a severe type of heart attack. Lovenox is already on the market in the U.S. for the treatment of a variety of cardiovascular problems.

The biotech company said that a Phase I/II study sponsored by the National Institutes of Health showed its orally administered typhoid-fever vaccine Ty800 triggered immune responses in more than 90% of the recipients.

Avant said that existing typhoid vaccines only offer protection rates of 50% to 80%.

The company, which estimates the market for typhoid vaccines at more than $200 million, plans to begin Phase II clinical trials at mid-year.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.